Ji Xi Shi

Researchers are evaluating the use of albumin combined with endovascular therapy in patients who have suffered an acute ischemic stroke in the anterior circulation. This prospective, multicenter, open-label, randomized controlled trial aims to verify the effectiveness and safety of adding albumin to the current standard endovascular treatment for this type of stroke. The study is sponsored by Capital Medical University and focuses on patients aged 18 to 80 years with specific stroke characteristics. Participants are randomly assigned to one of two groups one receiving albumin combined with endovascular treatment and the other receiving endovascular treatment alone. Albumin is given intravenously at a dose of 0.5 gkg up to 37.5 g on the first day and then daily on the second, third, and fourth days. Both groups receive acute stroke care and secondary prevention according to American stroke guidelines. Initial assessments include CT or MRI scans to locate the stroke and rule out bleeding, along with neurological and functional scoring. Throughout the study, patients undergo various evaluations such as the National Institutes of Health Stroke Scale NIHSS, Modified Rankin Scale mRS, Alberta Stroke Program Early CT Score ASPECTS, and quality of life assessments using standardized questionnaires. Vital signs and laboratory tests are monitored at baseline, with a 90-day follow-up conducted by telephone to assess recovery and outcomes. The primary measure is the proportion of patients achieving good functional recovery at 90 days after treatment.

Obesity greatly increases the risk of heart failure, and current treatments like caloric restriction, exercise, medications, or surgery may not be suitable for obese patients with heart failure. This research aims to study whether a combined approach using a diet management app and an intelligent weight scale can help obese patients with heart failure and reduced ejection fraction lose weight and improve their heart condition. The trial compares the effectiveness of a fully functional app and scale versus a limited-function version to assess their impact on heart failure outcomes and overall quality of life. Participants are randomly assigned to two groups one using a fully featured diet management app and intelligent weight scale with various monitoring tools and health metrics, and the other using a limited version of both. The full app tracks food intake, exercise, weight, and provides dietary analysis and recommendations, while the full scale measures body composition and vital signs. The limited versions offer fewer features. Participants use the app at every meal and weigh themselves daily for 12 months. During the study, participants will visit the clinic at 12 months for checkups. Researchers will evaluate outcomes such as a composite of death and heart failure hospitalizations over one year, changes in quality of life related to heart failure, and weight change. The trial includes monitoring of heart failure frailty and quality of life assessments at baseline, 3 months, and 1 year, with ongoing safety and condition tracking throughout the study period.